Filing Analysis
MiNK Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ending June 30, 2026. The filing serves as a formal announcement of earnings via a press release.
📋 Key Facts
- Report date: August 13, 2026
- Reporting period: Quarter ended June 30, 2026
- The company is an emerging growth company
- Financial results were furnished via press release (Exhibit 99.1)
MiNK Therapeutics held its Annual Meeting of Stockholders on June 17, 2026. Shareholders approved the election of three Class II Directors and ratified KPMG LLP as the independent auditor for the fiscal year ending December 31, 2026.
📋 Key Facts
- Annual Meeting held on June 17, 2026.
- Quorum reached with 3,277,906 shares (65.79% of outstanding/eligible shares) present or represented by proxy.
- Garo Armen, Barbara Ryan, and John Holcomb were elected to the Class II Board of Directors for three-year terms expiring in 2029.
- KPMG LLP was ratified as the independent registered public accounting firm for fiscal year ending Dec 31, 2026.
MiNK Therapeutics announced its financial results for the first quarter ended March 31, 2026. The announcement was made via a press release furnished as an exhibit to the filing.
📋 Key Facts
- The filing reports financial results for the fiscal quarter ended March 31, 2026.
- The report was filed on May 15, 2026, under Item 2.02 (Results of Operations and Financial Condition).
- A press release containing the detailed financial results was included as Exhibit 99.1.
MiNK Therapeutics announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The announcement was made via a press release furnished with the SEC on March 31, 2026.
📋 Key Facts
- The filing reports financial results for the quarter and year ended December 31, 2025.
- The report was filed under Item 2.02 (Results of Operations and Financial Condition).
- The company is classified as an emerging growth company.
- The press release was furnished as Exhibit 99.1.
MiNK Therapeutics issued a clarification regarding third-party rumors concerning potential combination trials for its lead candidate agenT-797 and potential strategic minority investments. The company confirmed active discussions are ongoing but noted that no binding agreements have been finalized.
🚩 Red Flags
- The mention of 'strategic minority investments' suggests the company may be seeking external capital, which could lead to future dilution.
📋 Key Facts
- Company is responding to third-party postings and investor inquiries regarding its clinical pipeline.
- Discussions are ongoing for combination trials involving agenT-797, an allogeneic iNKT cell therapy.
- The company is also in discussions regarding potential strategic minority investments.
- As of March 27, 2026, no binding arrangements have been reached or publicly disclosed.
MiNK Therapeutics appointed Melissa Orilall as Principal Financial Officer and Austin Charette as Principal Accounting Officer, effective March 13, 2026. Both individuals are employees of Agenus Inc. and will provide services to MiNK under an intercompany services agreement without direct compensation from the company.
🚩 Red Flags
- Reliance on related-party (Agenus) for essential Principal Financial Officer and Principal Accounting Officer functions.
- Potential conflicts of interest due to officers holding concurrent roles at the parent company.
📋 Key Facts
- Melissa Orilall appointed Principal Financial Officer on March 13, 2026.
- Austin Charette appointed Principal Accounting Officer on March 13, 2026.
- Both officers are current employees of Agenus Inc. and provide services via an Amended and Restated Intercompany Services Agreement.
- Neither officer receives direct compensation from MiNK Therapeutics.
- Ms. Orilall is VP of Global Financial Operations at Agenus; Mr. Charette is Senior Director of Financial Reporting and Compliance at Agenus.
MiNK Therapeutics, Inc. announced the resignation of Robert Kadlec, MD, from its Board of Directors, effective December 29, 2025. The departure is due to his acceptance of a senior government position as Assistant Secretary of War for Nuclear Deterrence and Chemical and Biological Defense Policy and Programs.
🚩 Red Flags
- None identified; resignation is due to external professional appointment rather than internal dispute or disagreement.
📋 Key Facts
- Robert Kadlec, MD resigned from the Board of Directors on December 29, 2025.
- Resignation includes all committee memberships.
- Reason for departure: Acceptance of a senior public service role in the U.S. government.
- Dr. Kadlec joined the Board in October 2024.
MiNK Therapeutics, Inc. filed this 8-K to provide financial results for the quarter ended September 30, 2025, which were previously released via press release but not timely reported on Form 8-K. The filing includes the press release and a transcript of the associated conference call.
🚩 Red Flags
- Late filing of required Form 8-K (administrative oversight).
📋 Key Facts
- Reporting period: Quarter ended September 30, 2025.
- The company acknowledged an inadvertent failure to timely file a Current Report on Form 8-K for the original press release.
- A live conference call was held on November 14, 2025, to discuss financial and operating results.
- No revisions were made to the previously presented results.
MiNK Therapeutics, Inc. announced the election of Dr. John Holcomb to its Board of Directors as a Class II director on September 23, 2025.
📋 Key Facts
- Dr. John Holcomb elected as Class II director effective September 23, 2025.
- Director term expires at the 2026 annual meeting of stockholders.
- Granted an option to purchase 4,174 shares of common stock under the 2021 Equity Incentive Plan.
- Option exercise price is equal to the Nasdaq closing price on the date of grant.
- Options vest over three years in equal annual installments subject to continued service.
MiNK Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2025. The filing serves as a formal announcement of earnings via a press release attached as Exhibit 99.1.
📋 Key Facts
- Report date: August 14, 2025
- Reporting period: Quarter ended June 30, 2025
- The filing includes results of operations and financial condition under Item 2.02
- Information is furnished but not 'filed' for purposes of Section 18 liability
MiNK Therapeutics entered into an At-Market Issuance Sales Agreement with B. Riley Securities to facilitate the sale of common stock up to a maximum aggregate offering price of $50,000,000.
🚩 Red Flags
- Potential for significant shareholder dilution via 'at-the-market' (ATM) offerings.
- The use of an ATM facility often indicates a need for immediate liquidity to fund operations.
📋 Key Facts
- Entered into an At Market Issuance Sales Agreement on July 15, 2025.
- Sales Agent: B. Riley Securities, Inc.
- Maximum aggregate offering price: $50,000,000.
- The issuance is pursuant to a previously filed Form S-3 registration statement (File No. 333-268143).
- Securities being sold are the Company's common stock.
MiNK Therapeutics announced the publication of a landmark case study in 'Oncogene' detailing complete remission in a metastatic, treatment-refractory testicular cancer patient using agenT-797. The company also highlighted positive Phase 2 data for gastric cancer presented at the AACR Immuno-Oncology meeting.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Publication in 'Oncogene' describes complete clinical, radiologic, and biochemical remission in a metastatic testicular cancer patient two years post-infusion.
- The treatment involved a single infusion of agenT-797 combined with nivolumab.
- No cytokine release syndrome (CRS) or graft-versus-host disease (GVHD) was observed in the reported case.
- Phase 2 trial data for 2L gastric cancer showed immune activation and early signals of tumor control, including extended survival beyond 12 months in several patients.
- The Phase 2 gastric cancer trial (NCT06251973) is currently actively enrolling.
MiNK Therapeutics held its Annual Meeting of Stockholders on June 18, 2025. Shareholders approved the election of two Class I directors, an option exchange proposal, and the ratification of KPMG LLP as independent auditors.
📋 Key Facts
- Annual Meeting held on June 18, 2025.
- Quorum reached with 2,793,022 shares (70.41% of outstanding/eligible shares) present or represented by proxy.
- Jennifer Buell and Ulf Wiinberg were elected to the Class I Board of Directors for three-year terms expiring in 2028.
- Proposal 2 (Option Exchange Proposal) was approved by stockholders.
- Proposal 3 (Ratification of KPMG LLP as independent auditor for FY ending Dec 31, 2025) was approved.
MiNK Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2025. The filing serves as a formal announcement of earnings via a press release.
📋 Key Facts
- Report date: May 15, 2025
- Reporting period: Quarter ended March 31, 2025
- The company is an emerging growth company
- Financial results were furnished via Exhibit 99.1 (Press Release)
MiNK Therapeutics, Inc. announced its financial results for the fiscal quarter and year ended December 31, 2024. The filing serves as a formal notice of the earnings release issued via press release.
📋 Key Facts
- Reporting period: Quarter and Year ended December 31, 2024.
- Announcement date: March 18, 2025.
- The filing includes an earnings press release as Exhibit 99.1.
MiNK Therapeutics, Inc. has approved a 1-for-10 reverse stock split following a special meeting of stockholders held on January 17, 2025. The split is scheduled to become effective at 12:01 a.m. ET on January 28, 2025.
🚩 Red Flags
- Reverse stock split (typically used to boost share price to meet exchange listing requirements)
- Significant dilution/consolidation of equity structure
📋 Key Facts
- Reverse stock split ratio: 1-for-10.
- Effective date of the reverse split: January 28, 2025, at 12:01 a.m. ET.
- Stockholders approved the amendment on January 17, 2025.
- The company's common stock will trade under a new CUSIP (603693 201) upon the opening of trading on January 28, 2025.
- Quorum was met with 27,582,512 shares present or represented by proxy out of 39,630,402 total shares outstanding at record date.
MiNK Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2024.
📋 Key Facts
- Report date: November 14, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) containing results of operations and financial condition.
- The information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
MiNK Therapeutics, Inc. announced the election of Dr. Robert Kadlec to its Board of Directors as a Class II director on October 30, 2024. The appointment includes membership on the Corporate Governance and Nominating Committee.
📋 Key Facts
- Dr. Robert Kadlec elected as Class II director effective October 30, 2024.
- Term expires at the company's annual meeting of stockholders in 2026.
- Dr. Kadlec will serve on the Corporate Governance and Nominating Committee.
- Granted an option to purchase 41,745 shares of common stock under the 2021 Equity Incentive Plan.
- Option exercise price is equal to the Nasdaq closing price on the date of grant; 10-year term with 3-year equal annual vesting.
MiNK Therapeutics announced that Chief Scientific Officer Dr. Marc Van Dijk will transition from his executive role to become a Scientific Advisory Board Member and Strategic Consultant, effective November 15, 2024.
🚩 Red Flags
- Departure of a key executive (CSO) can sometimes signal internal shifts or strategic changes in R&D direction.
📋 Key Facts
- Dr. Marc Van Dijk is stepping down as Chief Scientific Officer (CSO).
- The transition is scheduled to be effective on November 15, 2024.
- Dr. Van Dijk will remain associated with the company as a Scientific Advisory Board Member and Strategic Consultant.
- The filing was signed by CEO Jennifer Buell, Ph.D.
MiNK Therapeutics received a notice from Nasdaq stating it is in violation of the Minimum Value of Listed Securities (MVLS) rule. The company has 180 days to regain compliance by maintaining an MVLS of at least $35 million for ten consecutive trading days.
🚩 Red Flags
- Delisting notice from Nasdaq regarding minimum market value requirements.
- Failure to maintain a minimum market capitalization/liquidity threshold ($35M) over a 30-day period.
- Risk of delisting if compliance is not met by March 12, 2025.
📋 Key Facts
- Received MVLS Notice from Nasdaq on September 13, 2024.
- Violation: Minimum Value of Listed Securities (MVLS) was below $35.0 million for the previous 30 consecutive trading days.
- Compliance deadline: March 12, 2025 (180-day grace period).
- Requirement to regain compliance: MVLS must meet or exceed $35.0 million for at least ten consecutive trading days.
MiNK Therapeutics received formal notice from Nasdaq that it failed to regain compliance with the minimum $1.00 bid price requirement by the August 26, 2024 deadline. The company intends to request a hearing to stay delisting proceedings.
🚩 Red Flags
- Failure to meet minimum bid price requirement ($1.00) despite a 180-day grace period.
- Imminent risk of delisting from the Nasdaq Capital Market.
- Potential loss of liquidity and institutional investor interest if delisted.
📋 Key Facts
- The Company's common stock closed below $1.00 for 30 consecutive trading days prior to the grace period expiration.
- The 180-day grace period expired on August 26, 2024.
- Nasdaq issued formal notice of non-compliance on August 27, 2024.
- The Company intends to request a hearing before the Nasdaq Hearings Panel to stay delisting action.
MiNK Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2024. The filing serves as a formal notice of the earnings release issued via press release.
📋 Key Facts
- Reporting date: August 13, 2024
- Period covered: Quarter ended June 30, 2024
- The company is an emerging growth company.
- Financial results were furnished via Exhibit 99.1.
MiNK Therapeutics held its Annual Meeting of Stockholders on June 12, 2024. The meeting resulted in the successful election of two Class III directors and the ratification of KPMG LLP as the company's independent auditor.
📋 Key Facts
- Annual Meeting held on June 12, 2024.
- Quorum achieved with 28,359,271 shares (81.71% of outstanding/eligible shares) present or represented by proxy.
- Brian Corvese elected as Class III director for a three-year term expiring in 2027.
- Peter Behner elected as Class III director for a three-year term expiring in 2027.
- KPMG LLP ratified as the independent registered public accounting firm for fiscal year ending December 31, 2024.
MiNK Therapeutics entered into a Stock Purchase Agreement on May 13, 2024, to issue and sell 4.64 million shares of common stock at $1.25 per share. The transaction resulted in net proceeds of approximately $5.8 million.
🚩 Red Flags
- Significant dilution for existing shareholders via the issuance of 4.64 million shares.
- The Purchaser is granted voting control/alignment requirements until May 2025, which can impact corporate governance and shareholder autonomy.
- The sale was conducted without registration (reliance on Section 4(a)(2) and Regulation D), typical for distressed or fast-moving capital raises in micro-caps.
📋 Key Facts
- Issued and sold 4,640,000 shares of Common Stock.
- Sale price: $1.25 per share (representing a 25% premium to the 30-day VWAP).
- Net proceeds: Approximately $5.8 million after offering expenses.
- Transaction closed on May 14, 2024.
- The Company is required to file a registration statement for resale by August 15, 2024.
- Purchaser is subject to a lock-up period: no sales before November 9, 2024.
- Purchaser must vote in accordance with Board recommendations through May 14, 2025.
MiNK Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter ended March 31, 2024. The filing serves as a formal vehicle to furnish quarterly earnings information via a press release.
📋 Key Facts
- Reporting period: Quarter ended March 31, 2024
- Filing date: May 14, 2024
- The filing includes Exhibit 99.1 (Press Release) containing the financial results.
- Information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
MiNK Therapeutics, Inc. filed an 8-K to announce its financial results for the quarter and fiscal year ended December 31, 2023.
📋 Key Facts
- Reporting period: Quarter and Year ended December 31, 2023.
- Filing date: March 21, 2024.
- The filing includes a press release (Exhibit 99.1) detailing financial results.
- The information under Item 2.02 is furnished but not 'filed' for purposes of Section 18 liability.
MiNK Therapeutics received two separate deficiency notices from Nasdaq regarding its continued listing on the Nasdaq Capital Market. The company must address failures to meet Minimum Value of Listed Securities (MVLS) and Minimum Bid Price requirements.
🚩 Red Flags
- Delisting notice regarding Minimum Value of Listed Securities (MVLS)
- Delisting notice regarding Minimum Bid Price ($1.00 requirement)
- Dual non-compliance issues increase the risk of total delisting
- Uncertainty expressed by management regarding ability to regain compliance
📋 Key Facts
- Received MVLS Notice on February 23, 2024: MVLS was below $35.0 million for the previous 30 consecutive trading days.
- Compliance deadline for MVLS Rule is August 21, 2024 (180-day period).
- Received Minimum Bid Price Notice on February 26, 2024: Common stock failed to maintain a $1.00 minimum bid price for the previous 30 consecutive trading days.
- Compliance deadline for Minimum Bid Price Rule is August 26, 2024 (initial 180-day period).
- The company may be eligible for an additional 180-day compliance period for the bid price deficiency if certain criteria are met.
MiNK Therapeutics entered into a Convertible Promissory Note Purchase Agreement with Agenus Inc., allowing for the issuance of up to $5.0 million in convertible notes. The funds can be drawn down in increments as needed, providing flexible liquidity.
🚩 Red Flags
- Convertible debt can lead to significant dilution for existing shareholders upon conversion.
- The note includes a demand feature starting January 1, 2026, which creates a potential liquidity obligation.
📋 Key Facts
- Entered into a Convertible Promissory Note Purchase Agreement on February 12, 2024.
- The note has a principal amount of up to $5.0 million.
- Interest rate is set at 2% per annum, accruing from the date funds are advanced.
- Repayment of principal and interest is due on demand starting January 1, 2026.
- A 'qualified financing event' triggers Agenus's option to require repayment in cash or equity.